Patents by Inventor Colette Johnston

Colette Johnston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric antigen receptor with single domain antibody
    Patent number: 11866510
    Abstract: The invention relates to chimeric antigen receptors (CAR) that comprise one or more single human variable domain antibody and cells that express such CAR. In particular, the invention relates to CARs that include multiple single human variable domain antibodies. In a particular embodiment, the one or more single human variable domain antibody binds to prostate membrane antigen.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: January 9, 2024
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Brian McGuinness, Colette Johnston
  • Single domain antibodies to programmed cell death (PD-1)
    Patent number: 11814429
    Abstract: The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 14, 2023
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Bryan Edwards, Carolyn Edwards, James Legg, Martyna Lewandowska, Daniela Sydoruk, Colette Johnston, Christine Rossant, Yumin Teng
  • SINGLE DOMAIN ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 (PD-1)
    Publication number: 20230357405
    Abstract: The invention relates to PD-1 binding agents that block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: February 10, 2023
    Publication date: November 9, 2023
    Inventors: Phil HAYES, James LEGG, Martyna LEWANDOWSKA, Colette Johnston, Brian McGUINNESS, Mike ROMANOS, Christine ROSSANT, Yumin TENG
  • Single domain antibodies to programmed cell death protein 1 (PD-1)
    Patent number: 11591398
    Abstract: The invention relates to PD-1 binding agents that block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: February 28, 2023
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Phil Hayes, James Legg, Martyna Lewandowska, Colette Johnston, Brian McGuinness, Mike Romanos, Christine Rossant, Yumin Teng
  • Single Domain Antibodies to Programmed Cell Death (PD-1)
    Publication number: 20220306744
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: March 29, 2022
    Publication date: September 29, 2022
    Inventors: Carolyn EDWARDS, James LEGG, Martyna LEWANDOWSKA, Colette JOHNSTON, Christine ROSSANT, Yumin TENG
  • BINDING MOLECULES
    Publication number: 20220227850
    Abstract: The disclosure relates to single domain antibodies that bind human serum albumin and methods for using such single domain antibodies to extend the half life of therapeutic molecules.
    Type: Application
    Filed: May 15, 2020
    Publication date: July 21, 2022
    Inventors: Grainne DUNLEVY, Colette JOHNSTON, Daniela SYDORUK, Martyna LEWANDOWSKA
  • BINDING MOLECULES
    Publication number: 20220220215
    Abstract: The disclosure relates to multispecific agents that simultaneously bind CD137 and PD-1 and which comprise a single domain antibody specific to CD137 and a moiety that binds PD-1, for example a single domain antibody. The disclosure also relates to therapeutic and diagnostic applications of such agents, for example in the treatment of a cancer.
    Type: Application
    Filed: May 15, 2020
    Publication date: July 14, 2022
    Inventors: Carrie ENEVER, Colette JOHNSTON, James LEGG, Pavel PISA, Martyna LEWANDOWSKA, Iain SCOTT
  • Single-domain antibodies to programmed cell death 1 protein (PD-1), encoding nucleic acids and methods of using same
    Patent number: 11312771
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 26, 2022
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Carolyn Edwards, James Legg, Martyna Lewandowska, Colette Johnston, Christine Rossant, Yumin Teng
  • SINGLE DOMAIN ANTIBODIES TO PROGRAMMED CELL DEATH (PD-1)
    Publication number: 20200239570
    Abstract: The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: January 8, 2018
    Publication date: July 30, 2020
    Inventors: Bryan Edwards, Carolyn Edwards, James Legg, Martyna Lewandowska, Daniela Sydoruk, Colette Johnston, Christine Rossant, Yumin Teng
  • SINGLE DOMAIN ANTIBODIES TO PROGRAMMED CELL DEATH (PD-1)
    Publication number: 20200239573
    Abstract: The invention relates to PD-1 binding agents that block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: January 8, 2018
    Publication date: July 30, 2020
    Inventors: Phil Hayes, James Legg, Martyna Lewandowska, Colette Johnston, Brian McGuinness, Mike Romanos, Christine Rossant, Yumin Teng
  • Single Domain Antibodies to Programmed Cell Death (PD-1)
    Publication number: 20190322749
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: January 8, 2018
    Publication date: October 24, 2019
    Inventors: Carolyn Edwards, James Legg, Martyna Lewandowska, Colette Johnston, Christine Rossant, Yumin Teng
  • CHIMERIC ANTIGEN RECEPTOR WITH SINGLE DOMAIN ANTIBODY
    Publication number: 20190144561
    Abstract: The invention relates to chimeric antigen receptors (CAR) that comprise one or more single human variable domain antibody and cells that express such CAR. In particular, the invention relates to CARs that include multiple single human variable domain antibodies. In a particular embodiment, the one or more single human variable domain antibody binds to prostate membrane antigen.
    Type: Application
    Filed: May 8, 2017
    Publication date: May 16, 2019
    Inventors: Brian McGuinness, Colette Johnston